市場調查報告書
商品編碼
1433315
全球經導管肺動脈瓣市場 2023-2030Global Transcatheter Pulmonary Valve Market 2023-2030 |
預計在預測期(2023-2030年),全球經導管肺動脈瓣市場將以7.3%的CAGR成長。市場成長的關鍵因素包括風濕性心臟病、高血壓性心臟病、腦血管疾病和發炎性心臟病等各種心血管疾病(CVD)盛行率的增加。心臟瓣膜疾病人口的不斷成長和肺動脈瓣置換需求的激增是支持市場成長的主要因素。根據世界衛生組織 (WHO) 統計,2019 年估計有 1,790 萬人死於心血管疾病,佔全球死亡率的 32%。每年有超過 288,348 人死於風濕性心臟病,其中大部分生活在低收入或中等收入國家。據估計,全球有 12.8 億 30 至 79 歲的成年人患有高血壓,其中約三分之二居住在低收入和中等收入國家。此外,估計 46% 的成人高血壓患者並不知道自己患有這種疾病。
全球經導管肺動脈瓣市場根據技術和應用進行區隔。根據技術,市場分為球囊擴張式經導管瓣膜和自擴張式經導管瓣膜。此外,根據應用,市場區隔為心臟異常、肺動脈閉鎖、肺動脈狹窄、肺動脈瓣逆流等。其中,其他包括法洛氏四合症、動脈幹四聯症。在這些應用中,肺動脈瓣狹窄子區隔市場預計將佔據相當大的市場佔有率,因為其治療主動脈瓣狹窄和主動脈瓣逆流的可行性增強,且手術併發症發生率較低。
在這些產品中,球囊擴張經導管瓣膜區隔市場預計將在預測期內成長。此區隔市場的成長歸因於球囊擴張經導管瓣膜的採用率不斷提高以及產品開發和技術進步的數量不斷增加。因此,製造商被製造氣球膨脹技術所吸引,這反過來又推動了市場的成長。根據愛思唯爾 JACC:亞洲雜誌代表美國心臟病學會基金會於 2021 年 9 月發表的文章,新一代球囊擴張瓣膜 (BEV) 似乎是手術的有效替代方案,特別是在一些亞洲國家二尖瓣主動脈瓣的盛行率較高。適用於BEV 的多功能技術可以安全地治療異常、嚴重鈣化、較大的環形BAV,這些BAV 因室週白質軟化(PVL)、冠狀動脈阻塞、質子幫浦抑制劑(PPI) 和主動脈破裂的高風險而被認為不適合TAVR。
全球經導管肺動脈瓣市場根據地理位置進一步區隔,包括北美(美國和加拿大)、歐洲(英國、義大利、西班牙、德國、法國和歐洲其他地區)、亞太地區(印度、中國、日本、韓國和亞洲其他地區)以及世界其他地區(中東和非洲以及拉丁美洲)。其中,由於對創新心臟瓣膜的需求不斷成長、老年人口不斷增加以及醫療保健支出不斷增加,預計亞太地區將在預測期內實現成長。
由於醫療保健產業發達,以及肺動脈瓣狹窄和逆流等疾病盛行率不斷上升,預計北美將在經導管肺動脈瓣市場佔據顯著佔有率。此外,人們對創新心臟瓣膜的認知不斷提高,需求不斷增加,加上醫療保健支出不斷增加,預計將在預測期內推動市場成長。根據經濟合作暨發展組織(OECD)的數據,2021年,美國醫療保健支出佔國內生產毛額(GDP)的17.8%,幾乎是經合組織國家平均水準的兩倍。
根據美國醫療保險和醫療補助服務中心 (CMMS) 2022 年 3 月發布的資料,報告發現,2021-2030 年國民醫療支出年均成長預計為 5.1%,到 2030 年將達到近 6.8 兆美元同期國家國內生產毛額的年成長率預計為5.1%。根據可比較的預測成長率,預計 2030 年醫療保健佔 GDP 的佔有率將為 19.6%,與 2020 年 19.7% 的佔有率幾乎相同。因此,預計該國不斷成長的醫療保健支出將推動公司活動和政府在開發高效經導管肺動脈瓣方面的舉措,從而促進市場成長。
Global Transcatheter Pulmonary Valve Market Size, Share & Trends Analysis Report by Technology (Balloon-Expanded Transcatheter Valve, and Self-Expanded Transcatheter Valve), and by Application (Cardiac Anomaly, Pulmonary Atresia, Pulmonary Stenosis, Pulmonary Regurgitation, and Others), Forecast Period (2023-2030)
The global transcatheter pulmonary valve market is anticipated to grow at a CAGR of 7.3% during the forecast period (2023-2030). Pivotal factors attributed to market growth including increasing prevalence of various cardiovascular diseases (CVDs) such as rheumatic heart disorders, hypertensive heart diseases, cerebrovascular diseases, and inflammatory heart diseases. The growing population with heart valve disorders and surging demand for pulmonary valve replacement are major factors supporting the market growth. According to the World Health Organization (WHO), an estimated 17.9 million people were deceased from CVDs in 2019, representing 32% of all global mortalities. Rheumatic heart disease and claims over 288,348 lives each year the large majority in low- or middle-income countries. An estimated 1.28 billion adults aged 30 to 79 years globally have hypertension, among which around two-thirds living in low and middle-income countries. In addition, an estimated 46% of adults with hypertension are unaware that they have the condition.
The global transcatheter pulmonary valve market is segmented on the technology, and application. Based on the technology, the market is sub-segmented into balloon-expanded transcatheter valve and self-expanded transcatheter valve. Further, based on application, the market is sub-segmented into cardiac anomaly, pulmonary atresia, pulmonary stenosis, pulmonary regurgitation, and others. Where, others include tetralogy of fallot, truncusarteriosus. Among the application, the pulmonary stenosis sub-segment is anticipated to hold a considerable share of the market, owing to its enhanced feasibility of treating both aortic stenosis and aortic regurgitation with low rates of procedural complications.
Among the products, balloon-expanded transcatheter valve sub-segment is expected to grow over the forecast period. The segmental growth is attributed to the increasing adoption rate for balloon-expanded transcatheter valve and the growing number of product development, and technical advancement. Thus, manufacturers are attracted towards manufacturing balloon-expanded technology which in turn is propelling the market growth. According to the article published by Elsevier JACC: Asia journal, on behalf of The American College of Cardiology Foundation, in September 2021, new-generation balloon-expandable valve (BEV) appeared to be a valid alternative to surgery, especially in some Asian countries with a higher prevalence of bicuspid aortic valve. Versatile techniques applied to BEV could treat anomaly, heavily calcified, larger annular BAVs safely, which were considered ineligible in TAVR due to high risk of Periventricular leukomalacia (PVL), coronary artery obstruction, Proton pump inhibitors (PPIs), and aortic rupture.
The global transcatheter pulmonary valve market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, the Asia-Pacific region is anticipated to grow over the forecast period, owing to the growing demand for innovative heart valves, increasing geriatric population, and rising healthcare expenditure.
North America is expected to hold a prominent share in the transcatheter pulmonary valve market, owing to the presence of a well-developed healthcare sector, along with the rising prevalence of disorders such as pulmonary stenosis and regurgitation. Additionally, rising awareness and increasing demand for innovative heart valves, along with the rising healthcare expenditure are some other factors projected to drive the market growth over the forecast period. According to the Organization for Economic Co-operation and Development (OECD), in 2021, the US spent 17.8% of gross domestic product (GDP) on healthcare, nearly twice as much as the average OECD country.
As per the data published by the Centers for Medicare & Medicaid Services (CMMS), in March 2022, the report found that annual growth in national health spending is expected to average 5.1% over 2021-2030, and will reach nearly $6.8 trillion by 2030. Growth in the nation's GDP is also projected to be 5.1% annually over the same period. As a result of the comparable projected rates of growth, the healthcare share of GDP is expected to be 19.6% in 2030, nearly the same as the 2020 share of 19.7%. Thus, the growing healthcare spending in the country is anticipated to push company activities and government initiatives in developing efficient transcatheter pulmonary valves, in turn bolstering the market growth.
The major companies serving the global transcatheter pulmonary valve market include Boston Scientific Corp., Braile Biomedica, Medtronic PLC, Edwards Lifesciences Corp., Artivion, Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in February 2023, Medtronic PLC relaunched first-of-its-kind transcatheter pulmonary valve replacement system for treating congenital heart disease.